Who founded Renovo Rx?

Renovo Rx was founded by Ramtin Agah.

Who are Renovo Rx's investors?

Renovo Rx's investors include Astia.

How much funding has Renovo Rx raised?

Renovo Rx has disclosed $37.7M raised across 5 of its 7 known rounds.

Where is Renovo Rx headquartered?

Renovo Rx is headquartered in Mountain View, US.

Renovo Rx

NASDAQ: RNXT

Mountain View, US · Delaware corporation · 1 known investors

Find your way into Renovo Rx

215 people in our graph share verified history with the Renovo Rx team — schools, employers, funds. One of them is your warm intro.

Jerome Baileyunlockedknows Leesa Gentry · together at Omnicare Clinical Research (overlapped)

×3knows the team · via Achronix

knows the team · via Natus Medical

×5knows the team · via Aquantia

knows the team · via Ardian, Inc.

knows the team · via Renovo Rx

RenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.

Biotech Healthtech Medical Devices

Founders & leadership

Ramtin Agah Founder · Chief Medical OfficerRamtin Agah is a physician with background in medical devices, oncology, and healthcare information technology who trained at Cleveland Clinic and UCSF. He is Executive Officer of RenovoRx, which develops targeted oncology therapies and the RenovoCath, an FDA-cleared intra-arterial chemotherapy delivery device.

Shaun R. Bagai CEOShaun R. Bagai is an executive with experience in medical technology, including prior leadership roles in sales, marketing, clinical research, and physician training at both large corporations and growth-stage companies. He serves as Executive Officer and Director at RenovoRx, which develops targeted oncology therapies and the RenovoCath drug-delivery device for intra-arterial chemotherapy.

Leesa Gentry Chief Clinical OfficerLeesa Gentry is a clinical development executive with three decades of experience in therapeutic development and commercialization, including leadership roles in infectious disease programs, regulatory strategy, and clinical trial operations across biotech and pharmaceutical organizations.

Mark Voll Chief Financial OfficerMark Voll is an executive with over 30 years of experience as a CFO at technology companies, including early-stage startups and public corporations, and has overseen multiple initial public offerings. He serves as Executive Officer at RenovoRx, which develops targeted oncology therapies and the RenovoCath drug-delivery device for intra-arterial chemotherapy in cancer treatment.

Kamran Najmabadi FounderKamran Najmabadi brings experience in product development, operations, and strategy across the medical device and consumer electronics sectors, with background in electro-mechanical systems and product lifecycle management.

Board

Klaus HambuechenBoard director

Kirsten Angela MacfarlaneBoard director

Laurence J. MartonBoard director

Una S. RyanBoard director

Robert J. SpiegelBoard director

Investors · 1

Astialisted by AstiaSilicon Valley

Reported raises · per SEC filings

Form D private placements

$37.7M disclosed across 5 of 7 rounds · 1900–2026

▶$10MraisedApr 2026 · 16 investors · Biotechnology

Rule 506(b)